Loading...
Loading...
cryogenics-a-case-study-in-pharma-chilling-and-freezing
cryogenics-a-case-study-in-pharma-chilling-and-freezing

Cryogenics: A case study in pharma chilling and freezing

0

For French animal vaccine producer Ceva-Phylaxia, cryogenics technology plays a significant role in its day-to-day business. The company produces live, as well as inactivated, viral and bacterial vaccines across its 13 R&D centres and 23 production sites in 44 countries around the globe, which need to be frozen in controlled conditions and stored in liquid nitrogen. 

One of the fastest growing top 10 animal healthcare companies, Ceva-Phylaxia estimates a staggering 75% of all emerging human infectious diseases originate from animals and birds. These zoonoses, as they are known, are what compels the company to innovate and succeed in the fight against the likes of avian flu, brucellosis and Q-fever.

Ceva-Phylaxia works with welfare and social programmes around the world to bring its vision – ‘Together, beyond animal health’ – to life. From working with small-scale livestock owners and vets in Uganda, to supplying the biggest animal welfare charities in the UK and US with special calming collars to help rehome shelter dogs, Ceva-Phylaxia is a truly global company.

... to continue reading you must be subscribed

Subscribe Today

Paywall Asset Header Graphic

To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.

Please wait...